Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms

The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims to provide an assay to aid research on infections caused by Pseudomonas aeruginosa, delivering a solution to accelerate wound care research and reduce the reliance on mammalian testing.

The project focuses on developing an industrial whole organism assay for biofilms made by pathogenic bacteria without the use of laboratory rodents or mammals. The collaboration from Magnitude Biosciences, Perfectus Biomed Group and the University of Kent sees an exciting combination of knowledge and expertise sharing. University of Kent has expertise in developing new models to study host-microbe interactions and state-of-the-art facilities to monitor biofilms. Magnitude Biosciences are specialists in customised C. elegans studies, which accelerate research by offering a whole organism alternative to rodent and mammalian testing. Perfectus Biomed Group have extensive experience designing accredited and customisable biofilm testing methods. 

Companies producing chronic infection solutions currently test using in vitro models such as solid surface tests. Through this project Magnitude Biosciences, Perfectus Biomed and the University of Kent will develop colour-based assays to monitor biofilm formation by the pathogen Pseudomonas aeruginosa in the transparent nematode Caenorhabditis elegans (C. elegans). Assays using fluorescent markers and health readouts will be a faster and more cost-effective alternative to using rodents or mammals. This assay will provide data that better mimics clinical scenarios to support chronic infection research without the ethical implications associated with rodent and other mammalian testing.

Pseudomonas aeruginosa causes a large proportion of the infections that occur in hospitals such as chronic wound infection and chronic respiratory infections. Research that leads to products that improve and resolve these infections is critical for the development of life-changing and lifesaving treatments for patients.

To find out how Magnitude Biosciences can support your research contact us via info@magnitudebiosciences.com 

Press Contact:

Jessica Evans jess@magnitudebiosciences.com

Related Press Releases

Magnitude Biosciences: Revolutionising Research
Contract research organisation Magnitude Biosciences is projecting significant growth as it looks to...Read More
Life Sciences consortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant
Press Release: 24th July 2023 Photo:  From left to right: Prof Carrie Ambler, (LightOx) Dr Sam Whit...Read More
Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases
Photo: The Magnitude Biosciences Team May 2023, Sedgefield, United Kingdom Magnitude Biosciences Lim...Read More
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services
Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...Read More
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth
North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...Read More
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics
Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Durham, UK - July 29, 2021 Magnitude Biosciences, the world’s leading commercial lab services prov...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Magnitude Biosciences secures its second round of funding to support its pre-clinical research servi...Read More
Magnitude Biosciences announces new hires to support continued growth
Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs acr...Read More
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More

Get regular updates in your inbox

Sign up to our newsletter today, to get access to the latest company and industry news